Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.82 USD
Change Today +2.98 / 4.46%
Volume 19.4M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

mylan nv (MYL) Snapshot

Open
$66.48
Previous Close
$66.83
Day High
$72.16
Day Low
$66.31
52 Week High
04/9/15 - $72.62
52 Week Low
08/13/14 - $44.80
Market Cap
34.2B
Average Volume 10 Days
16.3M
EPS TTM
$3.00
Shares Outstanding
489.4M
EX-Date
07/17/07
P/E TM
23.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN NV (MYL)

mylan nv (MYL) Details

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, as well as active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. It offers generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. Further, the company manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. was founded in 1961 and is headquartered in Potters Bar, Hertfordshire.

25,000 Employees
Last Reported Date: 03/2/15
Founded in 1961

mylan nv (MYL) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $1.1M
President, Executive Director and Member of S...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan nv (MYL) Key Developments

Mylan Launches Norethindrone and Ethinyl Estradiol Tablets in US

Mylan has launched its Norethindrone and Ethinyl Estradiol tablets (chewable) 0.8mg/0.025mg and Ferrous Fumarate Tablets, 75mg (chewable) in the United States. These tablets are the generic version of United States-based pharmaceutical firm Warner Chilcott's Generess Fe tablets. The United States Food and Drug Administration has also provided final approval for the Famy Care, for its abbreviated new drug application for this product. The company is also offering a wide range of antiretroviral therapies, upon which around 40% of HIV/AIDS patients in developing countries depend.

Mylan Mulls Acquisitions

Mylan N.V. (NasdaqGS:MYL) is seeking acquisitions. Mylan wants to buy Perrigo for $205 per share, or $29 billion. The combined company would be able to grow even further with additional acquisitions.

Mylan Launches First Generic Version of Generess Fe®

Mylan N.V. announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess® Fe Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Mylan's immediate shipment of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable) represents the company's ninth oral contraceptive product launch in the U.S.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $69.82 USD +2.98

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,897 JPY -19.50
Becton Dickinson and Co $141.53 USD -0.86
Perrigo Co PLC $198.98 USD -0.02
Shire PLC 5,430 GBp -30.00
WW Grainger Inc $239.33 USD -2.54
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 29.9x
Price/Sales 3.4x
Price/Book 8.0x
Price/Cash Flow 36.8x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN NV, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.